Temporary Fecal Diversion in the Management of Colorectal and Perianal Crohn’s Disease

Table 1

Patient characteristics, details of stoma creation, and medication.

Total number of patients	29
Male : female	15 : 14
Median age (years)	30.0 (range, 18–76)
Median disease duration (years)	7.0 (range, 0–32)
Follow-up time (months)	33.0 (range, 3–103)
Medication at fecal diversion
Infliximab	14/26 (53.8%)
Adalimumab	8/26 (30.8%)
Azathioprine	16/26 (61.5%)
Methotrexate	5/26 (19.2%)
Mesalazine	3/26 (11.5%)
Steroids	10/26 (38.5%)
Type of fecal diversion
Loop ileostomy	25/29 (86.2%)
Loop colostomy	4/29 (13.8%)
Complications of stoma creation
Total	7/29 (24.1%)
Parastomal hernia	3/29 (10.3%)
Parastomal abscess	2/29 (6.9%)
Stoma prolapse	1/29 (3.4%)
Renal failure due to high output	1/29 (3.4%)
Medication during fecal diversion
Infliximab	5/25 (20%)
Adalimumab	10/25 (40%)
Azathioprine	6/25 (24%)
Methotrexate	1/25 (4%)
Mesalazine	1/25 (4%)
Steroids	5/25 (20%)